Approved for CME and ABIM MOC Part II Points from July 6, 2020 - July 6, 2021

Accreditation & CME Designation Statements:

HealthPartners is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

HealthPartners Office of Continuing Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Activity Objectives:

Following this learning activity, participants will be able to:

  • Recognize the different causes & presentations of angioedema
  • Distinguish between mast cell mediated and bradykinin-mediated angioedema
  • Identify potentially useful lab markers
  • Apply strategies to diagnose and treat angioedema
  • Discuss current and future therapeutic modalities

Faculty & Planning Committee:

Annely Richardson, MD; Catherine Nguyen, DO; Jeremy Springer, MD; Ruthann Wood

Dr. Richardson has indicated no conflicts of interest to disclose in relation to this presentation. She intends to discuss the off-label use of plasma-derived & recombinant C1 esterase inhibitor, icatibat, & ecallantide for non-hereditary, bradykinin-mediated angioedema, as well as the new drug application for berotralstat for hereditary angioedema.

The planning committee has indicated no potential conflicts of interest in relation to the planning of this activity.

Commercial Support:

There is no commercial support for this activity

Claiming CME Credit:

To claim CME credit, fill out the evaluation and credit verification using this link:


    • Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., Blessing-Moore, J., Cox, L., Nicklas, R. A., Oppenheimer, J., Portnoy, J. M., Randolph, C. R., Schuller, D. E., Spector, S. L., Tilles, S. A., & Wallace, D. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology, 133(5), 1270-1277.e66.
    • Drug Allergy: An Updated Practice Parameter. (2010). Annals of Allergy, Asthma & Immunology, 105(4), 259-273.e78.
    • Konate, M., Wilkinson, M. J., Taylor, J., Scott, E. S., Berger, B., & Rodriguez Lopez, C. M. (2020). Greenhouse Spatial Effects Detected in the Barley (Hordeum vulgare L.) Epigenome Underlie Stochasticity of DNA Methylation. Frontiers in Plant Science, 11, 59–63.
    • Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., Khan, D., Ledford, D., Lieberman, J., Metcalfe, D., Nowak-Wegrzyn, A., Sicherer, S., Wallace, D., Blessing-Moore, J., Lang, D., … Tilles, S. A. (2015). Anaphylaxis—a practice parameter update 2015. Annals of Allergy, Asthma & Immunology, 115(5), 341–384.
    • Lee, J. K., & Simpson, R. S. (2019). Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. The Journal of Allergy and Clinical Immunology: In Practice, 7(5), 1659-1661.e1.
    • Marcus Mauer, MD, M. M. (2020). Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 382(6), 579–580.
    • Craig, T. J., Bernstein, J. A., Farkas, H., Bouillet, L., & Boccon-Gibod, I. (2014). Diagnosis and Treatment of Bradykinin-Mediated Angioedema: Outcomes from an Angioedema Expert Consensus Meeting. International Archives of Allergy and Immunology, 165(2), 119–127.
    • Busse, MD, P. B., & Christiansen, MD, S. C. (2020). Hereditary Angioedema. New England Journal Of Medicine, 382, 1136–1148.
    • Nzeako, U. C. (2001). Hereditary Angioedema. Archives of Internal Medicine, 161(20), 2417.
    • Banerji, A., Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., Davis-Lorton, M., Zanichelli, A., Li, H. H., Craig, T., Jacobs, J., Johnston, D. T., Shapiro, R., Yang, W. H., Lumry, W. R., … Maurer, M. (2018). Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. JAMA, 320(20), 2108.